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Abstract: Celiac disease (CD) is an autoimmune enteropathy linked to alterations of metabolism.
Currently, limited untargeted metabolomic studies evaluating differences in the plasma metabolome
of CD subjects have been documented. We engage in a metabolomic study that analyzes plasma
metabolome in 17 children with CD treated with a gluten-free diet and 17 healthy control siblings in
order to recognize potential changes in metabolic networks. Our data demonstrates the persistence
of metabolic defects in CD subjects in spite of the dietary treatment, affecting a minor but signifi-
cant fraction (around 4%, 209 out of 4893 molecular features) of the analyzed plasma metabolome.
The affected molecular species are mainly, but not exclusively, lipid species with a particular affec-
tation of steroids and derivatives (indicating an adrenal gland affectation), glycerophospholipids
(to highlight phosphatidic acid), glycerolipids (with a special affectation of diacylglycerols), and fatty
acyls (eicosanoids). Our findings are suggestive of an activation of the diacylglycerol-phosphatidic
acid signaling pathway in CD that may potentially have detrimental effects via activation of several
targets including protein kinases such as mTOR, which could be the basis of the morbidity and
mortality connected with untreated CD. However, more studies are necessary to validate this idea
regarding CD.
Keywords: celiac disease; diacylglycerols; fatty acyls; glycerophospholipids; mass spectrometry;
plasma metabolomics; steroids
1. Introduction
Celiac disease (CD) is an enteropathy of autoimmune origin with a systemic and
chronic trait generated by the dietary gluten and related prolamins in individuals with
genetic susceptibility [1,2]. CD appears and develops from the dysfunctional interaction
between genetic and environmental factors [3]. The affected subjects, usually children but
also adults, display an inflammatory enteropathy with different degrees of severity [4] and
clinical manifestations that range from asymptomatic to a wide variety of digestive and/or
systemic signs and symptoms. Furthermore, untreated symptomatic CD patients develop
relevant morbidity and mortality [5]. Thus, it can be associated to CD-related neurologic
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diseases; osteoporosis; T-cell lymphoma; and autoimmune endocrine diseases such as
Addison’s disease, diabetes (type I), and tiroiditis [5]. Fortunately, when celiac patients
are treated with a strict gluten-free diet (GFD), the clinical and histological manifestations
reverse [1]. Recent studies indicate that CD affects about 1–3% of the general population in
both North America and Europe [6–8].
The genetic predisposition of CD is linked to specific class II major histocompatibility
complex (MHC) alleles. Thus, the HLA-DQ2 allele is present in more than 90% of CD
subjects, whereas the DQ8 allele is present in the remaining 10% of CD patients; importantly,
non-HLA genes have been described to contribute to the disease [9]. As around 40–50%
of the European general population is positive for the HLA-DQ2 heterodimer [10], it is
evident that additional factors are required for the onset and progression of the CD.
Alterations in metabolism seem to also be present in CD. Thus, metabolomic studies,
despite being restricted to the use of NMR (nuclear magnetic resonance)-based methods,
suggest lesser but significant changes in metabolites belonging to microbiome-derived
metabolites, lipid metabolism, and energy metabolism [11–16]. Remarkably, differences
in methionine, choline, and choline-derived lipids content in CD subjects were described,
suggestive of an affectation of one-carbon metabolism. This alteration of methionine
metabolism in CD subjects was recently confirmed and extended using a LC–MS/MS
approach [17]. In this study, a down-regulation of the trans-sulphuration pathway in CD
patients was observed, in particular.
Currently, no untargeted metabolomic analysis using LC-MS/MS or investigations
regarding changes in the plasma metabolome of CD subjects have been conducted. For this
reason, we designed a metabolomic study with 34 subjects including 17 CD patients and
17 healthy control siblings. The CD subjects were children under a GFD treatment. This
election was based on the idea that GFD induces the return of CD signs and symptoms to
a healthy state as well as induces histological changes and changes in metabolism. In ad-
dition, potential persistent metabolic alterations should be, if present, specific to the CD
condition. Blood plasma was used because it is easy to obtain and is the main carrier of
metabolites in the body, being well-known as the compositional profile of this biological
fluid [18]. Furthermore, its composition is under strict control despite the continuous
change induced by different internal and external conditions in physiological and patho-
logical states [19,20]. These facts allow us to ensure the identification of new molecular
mechanisms and targets that may lead to healthier states. The plasma metabolome profile
was defined using an LC–MS/MS platform to discriminate specific phenotypic patterns
linked to genotypes of CD.
2. Materials and Methods
2.1. Subjects
We performed a cross-sectional study in which 17 CD children and 17 healthy control
siblings between 4 and 17 years of age were included from January to December of 2018.
The study was carried out in the Gastroenterology, Hepatology, and Child Nutrition Service
from the “Virgen de las Nieves” University Hospital in Granada, Spain. The diagnosis of
CD was made following the European Society for Pediatric Gastroenterology Hepatology
and Nutrition (ESPGHAN) criteria of 2012 [21]. Infants with liver or kidney diseases,
inflammatory bowel disease, diabetes, and chronic asthma and those consuming dietary
supplements containing substances with antioxidant activity were excluded. We also
excluded obese patients (according to the criteria of the International Task Force) [22].
All patients signed the written informed consent document and excluded those other-
wise from the study. The Ethics Committee of the University of Granada approved the
study (reference number 201202400000697), and the Good Clinical Practice guidelines
were followed.
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2.2. Clinical and Sociodemographics
Participants’ clinical and sociodemographic traits, including adherence to the nutri-
tional intervention (GFD), were evaluated by the same research team.
2.3. Anthropometric Measures
Anthropometric traits (height and weight) were measured in healthy control and
CD subjects. Height was determined to the nearest 5 mm using a stadiometer (Seca 22,
Hamburg, Germany). Body weight was determined using a mechanical balance scale
(Seca200, Hamburg, Germany).
2.4. Blood Samples
Blood samples were obtained via venipuncture in the morning (between 07:00 and
08:00 A.M.) after fasting overnight (8–10 h) and collected in one vacutainer CPT (cell prepa-
ration tube; BD, Franklin Lakes, NJ, USA) containing sodium heparin as an anticoagulant.
Blood samples were centrifuged, and plasma fractions were collected, immediately frozen




All reagents were obtained from Sigma-Aldrich and of the highest purity available
unless otherwise specified.
2.5.2. Sample Processing
Plasma metabolites’ extraction was made on the basis of a previously described
methodology [23]. In brief, 10 µL of plasma was mixed with 30 µL of cold methanol
containing 1 µg/mL of Phe-13C as the internal standard and 1 µM BHT as the antioxidant.
After incubation at 4 ◦C for 60 min, the samples were centrifuged at 12,000× g for 3 min.
Then, the supernatant was filtrated (CLS8169, Sigma, Madrid, Spain) and transferred
to vials with glass inserts (Agilent, Barcelona, Spain) for chemical analysis. Samples
were decoded and randomized before the LC-MS analysis. To serve as quality control
for metabolite extraction, a pool of plasma samples with internal Phe-13C was used and
injected every 5 samples.
2.5.3. Analysis Conditions
Two microliters of metabolic extract were analyzed according to a previously described
method [23]. A reversed-phase column (Zorbax SB-Aq 2.1 × 50 mm, 1.8 µm particle size,
Agilent Technologies, CA, USA) with a pre-column (Zorbax SB-C8 Rapid Resolution
Cartridge, 2.1 × 30 mm, 3.5 µm particle size, Agilent Technologies, CA, USA) set at 60 ◦C
was used for chromatographic separation [23]. Afterwards, electrospray ionization was
made in positive and negative ion modes using N2 at a pressure of 50 psi for the nebulizer
with a flow of 12 L/min and a temperature of 325 ◦C.
The analysis was performed using a UHPLC 1290 model coupled to a Q-TOF 6545 in-
strument (Agilent Technologies, CA, USA) as previously described [23], and data were
collected using the MassHunter Data Analysis Software (Agilent Technologies, CA, USA).
2.6. Data Analyses
Mass Hunter Qualitative Analysis Software (Agilent Technologies, Barcelona, Spain)
was used to obtain samples’ molecular features, representing different co-migrating ionic
species of a given molecular entity using the Molecular Feature Extractor (MFE) algo-
rithm (Agilent Technologies, Barcelona, Spain). The Mass Hunter Mass Profiler Profes-
sional Software (Agilent Technologies, Barcelona, Spain) was used to make an untargeted
metabolomic analysis over the extracted features. Only features with a minimum of 2 ions
were selected. Then, the molecular traits in the samples were aligned using a retention time
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window of 0.1% ± 0.25 min and 30.0 ppm ± 2.0 m Da. Only features found in at least 70%
of the QC samples and with less than 20% of relative standard deviation among QC sam-
ples were considered to correct for individual bias. Instrumental drift was corrected using
a LOESS approach [24,25]. Multivariate statistics (Principal Component Analysis (PCA),
Partial Least Squares-Discriminant Analysis (PLSDA), and Hierarchical and Classification
Analyses) were performed using the Metaboanalyst software [26,27].
Statistical analyses were conducted using R version 3.6.1. [28] A paired-t-test was
used to evaluate sibling differences in clinical and MS comparisons between groups.
The minimum signification level was set at p < 0.05 without multiple-testing adjustment,
and Benjamini–Hochberg’s False Discovery Rate (FDR) p-values are reported as comple-
mentary information. Heatmaps and forest plots were performed using the heatmap and
forest plot packages, respectively [29,30].
Features were defined by the exact mass and retention time using HMDB [31] (accu-
racy < 30 ppm) and PCDL database (Agilent Technologies, Barcelona, Spain), which uses
retention times in a standardized chromatographic system as an orthogonal searchable
parameter to complement accurate mass data (accurate mass retention time approach) [32].




The baseline clinical traits of the study population are shown in Table 1. A total of
34 children were included in the study, 17 CD and 17 healthy siblings. There were no
differences between groups, including factors that could affect metabolomics’ profile such
us dietary habits and physical activity.
Table 1. Demographic and biological characteristics of the study population.
Trait Healthy Siblings (n = 17) Celiac Children (n = 17) p-Value
Sex (female, n (%)) 10 (58.8) 13 (76.4) 0.271
Age (years) 11.25 (4.23) 9.39 (2.77) 0.145
Weight (kg) 38.54 (16.9) 30 (9.63) 0.082
Height (cm) 140.66 (20.32) 131.2 (19.56) 0.178
BMI (kg/m2) 18.5 (3.98) 17 (1.58) 0.166
Mediterranean diet (MD) adherence (n (%))
Low 1 (5.9) 1 (5.9)
Medium 8 (47.1) 7 (41.2) 0.936
High 7 (41.2) 8 (47.1)
Gluten-free diet (GFD) 0 17




HLA DQ8+ 0 0
HLA-DQ2 + DQ8+ 1 3
Values shown as mean (standard deviation) unless otherwise indicated.
3.2. Untargeted Metabolomics
With the aim to analyze the effect of the celiac condition in the whole circulating
metabolome, an untargeted metabolomic analysis was performed. Baseline correction,
peak picking, and peak alignment were determined based on acquired data, resulting in
a total of 48,952 molecules from both ionization modes (positive and negative). After qual-
ity control assessment, filtering, and correction of the signal, 4893 features remained
that were used for statistical analysis. Multivariate statistics suggest that there is not
a specific metabolomic signature associated with the celiac condition (data not shown),
but when we searched for specific celiac biomarkers, we found 209 molecules statistically
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different between groups and five of them (lithocholyltaurine, 18-Oxocortisol, 5alpha-
Pregnan-3alpha, 20beta-diol disulfate, and an unidentified compound, all up-regulated
in CD individuals) retained their significance after applying Benjamini–Hochberg’s FDR
(Supplementary Dataset). Among all of the significant molecules, 36 of them were an-
notated (Figures 1 and 2), wherein 23 (64%) were increased and 13 (36%) decreased in
CD patients. Specifically, we described two carboxylic acids and derivates increased in
CD, four fatty acyls, five glycerolipids, eleven glycerophospholipids, one organoxigen
compound, and two sphingolipids were affected by the CD condition. Furthermore, among
36 molecules with a potential identity, eight of them were lipid species belonging to steroid
metabolism and two were involved in bilirubin metabolism. Interestingly, nine of these
identified molecules have been involved in cell signalling pathways (diacylglycerides (DG),
lysophospholipids, and ceramides) and are mainly increased in CD subjects.
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Figure 1. Putatively annotated plasma metabolites significantly different in CD subjects compared to healthy siblings. Levels
of statistically significant molecules are represented using a heatmap. Each line of the heatmap represents a lipid species
colored by its abundance intensity normalized with an internal standard, log-transformed, and auto-scaled. The scale
from blue to red indicates the normalized abundances in arbitrary units. All compounds are putatively annotated based
on physicochemical properties and/or spectral similarity with public/commercial spectral libraries [33]. (a) ID based
on exact mass, RT, and MS/MS spectrum; (b) ID based on exact mass and RT; and (c) ID based on MS/MS spectrum.
PC(XX): the specific phosphatidylcholine species could not be annotated, but its MS/MS spectrum displayed a PC-
characteristic pattern.
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Figure 2. Lipid metabolism seems to be preferentially affected by CD. Levels of statistically significant molecules are
represented using a forest plot. Forest plot dots represent the estimated difference in means, and the whiskers represent the
confidence intervals. All compounds are putatively annotated based on physicochemical properties and/or spectral similar-
ity with public/commercial spectral libraries [33]. (a) ID based on exact mass, RT, and MS/MS spectrum (high fiability);
(b) ID based on exact mass and RT; and (c) ID based on MS/MS spectrum. PC(XX): the specific phosphatidylcholine species
could not be annotated, but its MS/MS spectrum displayed a PC-characteristic pattern.
4. Discussion
The variability in clinical manifestations of CD is due to the interindividual differential
vulnerability supported by genetic, immunological, and environmental factors. Regarding
the diversity of signs and symptoms generated by CD, recent observations suggest that
metabolic alterations in subjects with CD must also be considered. Although in most
cases nowadays the diagnosis of CD requires confirmation by a positive biopsy, a better
understanding of the metabolic processes underlying this pathology could offer the oppor-
tunity to uncover potential new physiopathological mechanisms and biomarkers useful for
the diagnosis of doubtful cases due to the histological results as well as for follow-up of
the disease.
Effectively, available evidence from metabolomic studies certified the presence of
minor but significant differences in the metabolic profile between healthy individuals and
celiac patients (children and adults) [11–17]. In these studies, using NMR or MS-based
methods, biological samples from different origins including faecalis material, plasma,
serum, and urine were analyzed. Overall, the metabolomic changes described are asso-
ciated with modifications in gut microflora and/or intestinal permeability, malabsorp-
tion, and alterations in metabolism [11–17]. Thus, lower concentrations of amino acids
(asparagine, isoleucine, methionine, proline, and valine); diverse metabolites (choline,
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creatinine, lactate, lipids (phosphatidylcholines), methylamine, methylglutarate, and pyru-
vate); and higher levels of 3-hydroxybutyric acid, glucose, and triacyl glycerides were the
main differences observed in the serum metabolome between CD subjects and healthy
controls [11–16]. It is also particularly remarkable that the decreased levels of choline, me-
thionine, and phosphatidylcholines [15,16] along with the decreased content of metabolites
in the trans-sulphuration pathway [17] clearly suggest defects in the one-carbon metabolism
in CD. Importantly, these studies also verified that the introduction of a strict GFD seems
to quasi completely reverse the metabolic profile of CD subjects to the healthy condition.
In the present study, our findings demonstrate the persistence of alterations in the
whole circulating metabolome of CD patients in spite of dietary intervention. These
metabolomic changes are, however, minor as only 209 metabolites seem to be affected,
which represent only around 4% of the total plasma metabolome analyzed. Unfortunately,
among these 209 metabolites, only 36 were identified, with 23 (64%) increased and 13 (36%)
decreased in CD. Interestingly, we identified that molecules mainly belong to lipid families
and are involved in cell signaling (DG, lysophospholipids, and ceramides). These lipid
species are mostly increased in CD. Furthermore, we found fatty acid derivates involved in
inflammatory pathways such as leukotrienes and thromboxanes. Remarkably, eight of the
lipid species identified belonged to steroid metabolism and two of them were involved
in bilirubin metabolism, suggesting potential alterations at the hepatic level as well as in
the endocrine system and, in particular, the adrenal gland. Although it has been described
that endocrine manifestations occur in celiac disease [34], this is the first time that potential
alterations affecting the functioning of the adrenal gland are reported. More studies,
however, are necessary to explore this idea in CD.
Among the observed changes in lipid molecular species, the increased content of
DG (three species) and phosphatidic acid (PA) (one species) is particularly relevant and
requires special attention. DG has exclusive functions as a constituent of cell membranes,
intermediate in lipid metabolism and lipid-mediated signaling, and their levels are strictly
regulated [35]. DG signals are particularly relevant in neuronal and immune tissues, play-
ing a central role in the control of neuron communication, phagocytosis, and the control of
immune responses [36]. Simply put, DG is generated by hydrolysis of phosphatidylinositol
4,5-bisphosphate, which is also the substrate for phosphatidylinositol 3 kinase activity.
DG is phosphorylated in a reaction catalyzed by DG kinases to generate PA, the first
step in a series of reactions that replenish phosphatidylinositol 4,5-bisphosphate levels
in the phosphatidylinositol cycle. Other DG sources include the pool generated from
PC (phosphatidylcholine) and ceramides [36]. Importantly, DG and PA, as lipid second
messengers, play important roles in regulating several target proteins including numer-
ous protein kinases such as mTOR [37], among several others. Interestingly, a sustained
inflammatory response mediated by the activation of mTOR in CD has been recently de-
scribed [38]. Therefore, our findings suggest potential defects of these biological processes
subsequently to the up-regulation of DG metabolism and for which the consequences
should be evaluated in CD patients.
Regarding limitations, the present study’s sample size was relatively small, and con-
sequently, the results must be interpreted with caution. P-values were not adjusted for
multiple testing; thus, the results should be further validated with complementary tech-
niques. The fact that five of the celiac children were on a GFD for less than 12 months could
influence the results, considering a long-term GFD could act on the metabolic pathways
after 12 months, as other studies demonstrated within an adult population [11]. However,
this is the first sibling-based metabolomic approach in pediatric CD. Moreover, the fact that
study participants were matched with their siblings reduces the differences that can occur in
metabolomic processes [39], which could be influenced by several factors, thus decreasing
the variability. Another limitation that should be considered is that glycerophospholipid
metabolism could not be fully assessed because the metabolite extraction method used is
thought to extract more polar components and triacyl glycerides were not extracted and
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detected. Consequently, the potential role of these molecules as bioenergetics sources has
been dismissed.
In conclusion, our results suggest the persistence of minor but significant alterations in
the lipid metabolism of CD subjects, despite being under a GFD, that can be an expression
of a new biological mechanism underlying the CD pathology, which requires further
studies to be verified.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/nu13072271/s1, Supplementary Dataset: Plasma metabolome data from CD subjects.
Author Contributions: Conceptualization, R.M.-M., R.P. and T.N.; metabolomic analyses, J.D.G.-L.,
N.M.-M., J.S., M.J. and R.P.; writting—original draft, R.M.-M., M.J., N.M.-M., R.P. and T.N.; writing—
review and editing, R.M.-M., M.J., N.M.-M., R.P., J.M. and T.N.; project administration, T.N.; fund-
ing acquisition, J.M. and T.N. All authors have read and agreed to the published version of the
manuscript.
Funding: This research was funded by the Regional Government of Andalusia, Excellence Research
(Project No P12-AGR-2581); by the Spanish Ministry of Science, Innovation, and Universities (Minis-
terio de Ciencia, Innovación y Universidades, RTI2018-099200-BI00); by the Generalitat of Catalonia:
Agency for Management of University and Research Grants (2017SGR696); and by the Department
of Health (SLT002/16/00250) to R.P. This study was co-financed by FEDER funds from the European
Union (“A way to build Europe”). IRBLleida is a CERCA Programme/Generalitat of Catalonia.
The study was also partially funded by the grant “Investigation grant program by the Association of
Celiacs and Sensitive to Gluten of the Community of Madrid”.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki, and approved by the Ethics Committee of the University of Granada
(Ref. 201202400000697).
Informed Consent Statement: Written informed consent was obtained from all subjects involved in
the study.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: M.J. is a “Serra Húnter” Fellow. N.M.-M. was supported by the Generalitat of
the Catalonia Predoctoral Fellowship (AGAUR, ref 647 2018FI_B2_00104). J.D.G-L. was supported by
the University of Lleida Predoctoral Fellowship. Rafael Martín-Masot is grateful to the PhD program
“MedicinaClínica y SaludPública” from the University of Granada; published results are part of his
doctoral thesis.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Farrell, R.J.; Kelly, C.P. Celiac Sprue. N. Engl. J. Med. 2002, 346, 180–188. [CrossRef]
2. Green, P.H.; Jabri, B. Coeliac disease. Lancet 2003, 362, 383–391. [CrossRef]
3. Schuppan, D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000, 119, 234–242. [CrossRef] [PubMed]
4. Kagnoff, M.F. Celiac disease: Pathogenesis of a model immunogenetic disease. J. Clin. Investig. 2007, 117, 41–49. [CrossRef]
[PubMed]
5. Corrao, G.; Corazza, G.R.; Bagnardi, V.; Brusco, G.; Ciacci, C.; Cottone, M.; Guidetti, C.S.; Usai, P.; Cesari, P.; Pelli, M.A.; et al.
Mortality in patients with coeliac disease and their relatives: A cohort study. Lancet 2001, 358, 356–361. [CrossRef]
6. Mäki, M.; Mustalahti, K.; Kokkonen, J.; Kulmala, P.; Haapalahti, M.; Karttunen, T.; Ilonen, J.; Laurila, K.; Dahlbom, I.; Hansson, T.;
et al. Prevalence of Celiac Disease among Children in Finland. N. Engl. J. Med. 2003, 348, 2517–2524. [CrossRef]
7. Fasano, A.; Catassi, C. Current approaches to diagnosis and treatment of celiac disease: An evolving spectrum. Gastroenterology
2001, 120, 636–651. [CrossRef]
8. Kivelä, L.; Kurppa, K. Screening for coeliac disease in children. Acta Paediatr. 2018, 107, 1879–1887. [CrossRef]
9. Romanos, J.; van Diemen, C.C.; Nolte, I.M.; Trynka, G.; Zhernakova, A.; Fu, J.; Bardella, M.T.; Barisani, D.; McManus, R.;
van Heel, D.; et al. Analysis of HLA and Non-HLA Alleles Can Identify Individuals at High Risk for Celiac Disease. Gastroenterol-
ogy 2009, 137, 834–840.e3. [CrossRef]
Nutrients 2021, 13, 2271 9 of 10
10. Kårhus, L.L.; Thuesen, B.; Skaaby, T.; Rumessen, J.J.; Linneberg, A. The distribution of HLA DQ2 and DQ8 haplotypes and
their association with health indicators in a general Danish population. United Eur. Gastroenterol. J. 2018, 6, 866–878. [CrossRef]
[PubMed]
11. Bertini, I.; Calabrò, A.; De Carli, V.; Luchinat, C.; Nepi, S.; Porfirio, B.; Renzi, D.; Saccenti, E.; Tenori, L. The Metabonomic
Signature of Celiac Disease. J. Proteome Res. 2009, 8, 170–177. [CrossRef]
12. Bernini, P.; Bertini, I.; Calabrò, A.; La Marca, G.; Lami, G.; Luchinat, C.; Renzi, D.; Tenori, L. Are Patients with Potential Celiac
Disease Really Potential? The Answer of Metabonomics. J. Proteome Res. 2011, 10, 714–721. [CrossRef]
13. Di Cagno, R.; De Angelis, M.; De Pasquale, I.; Ndagijimana, M.; Vernocchi, P.; Ricciuti, P.; Gagliardi, F.; Laghi, L.; Crecchio, C.;
Guerzoni, E.M.; et al. Duodenal and faecal microbiota of celiac children: Molecular, phenotype and metabolome characterization.
BMC Microbiol. 2011, 11, 219. [CrossRef] [PubMed]
14. Sellitto, M.; Bai, G.; Serena, G.; Fricke, W.F.; Sturgeon, C.; Gajer, P.; White, J.R.; Koenig, S.S.K.; Sakamoto, J.; Boothe, D.; et al. Proof
of Concept of Microbiome-Metabolome Analysis and Delayed Gluten Exposure on Celiac Disease Autoimmunity in Genetically
At-Risk Infants. PLoS ONE 2012, 7, e33387. [CrossRef] [PubMed]
15. Kirchberg, F.F.; Werkstetter, K.J.; Uhl, O.; Auricchio, R.; Castillejo, G.; Korponay-Szabo, I.R.; Polanco, I.; Ribes-Koninckx, C.;
Vriezinga, S.L.; Koletzko, B.; et al. Investigating the early metabolic fingerprint of celiac disease—A prospective approach.
J. Autoimmun. 2016, 72, 95–101. [CrossRef]
16. Sen, P.; Carlsson, C.; Virtanen, S.M.; Simell, S.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.; Hyötyläinen, T.; Knip, M.; et al.
Persistent Alterations in Plasma Lipid Profiles Before Introduction of Gluten in the Diet Associated With Progression to Celiac
Disease. Clin. Transl. Gastroenterol. 2019, 10, e00044. [CrossRef]
17. Martín-Masot, R.; Mota-Martorell, N.; Jové, M.; Maldonado, J.; Pamplona, R.; Nestares, T. Alterations in One-Carbon Metabolism
in Celiac Disease. Nutrients 2020, 12, 3723. [CrossRef]
18. Psychogios, N.; Hau, D.D.; Peng, J.; Guo, A.C.; Mandal, R.; Bouatra, S.; Sinelnikov, I.; Krishnamurthy, R.; Eisner, R.; Gautam, B.;
et al. The Human Serum Metabolome. PLoS ONE 2011, 6, e16957. [CrossRef]
19. Jové, M.; Maté, I.; Naudí, A.; Mota-Martorell, N.; Portero-Otín, M.; De La Fuente, M.; Pamplona, R. Human Aging Is a Metabolome-
related Matter of Gender. J. Gerontol. Ser. A Boil. Sci. Med. Sci. 2016, 71, 578–585. [CrossRef] [PubMed]
20. Burla, B.; Arita, M.; Arita, M.; Bendt, A.K.; Cazenave-Gassiot, A.; Dennis, E.A.; Ekroos, K.; Han, X.; Ikeda, K.; Liebisch, G.; et al.
MS-based lipidomics of human blood plasma: A community-initiated position paper to develop accepted guidelines. J. Lipid Res.
2018, 59, 2001–2017. [CrossRef]
21. Husby, S.; Koletzko, S.; Korponay-Szabó, I.; Mearin, M.; Phillips, A.; Shamir, R.; Troncone, R.; Giersiepen, K.; Branski, D.;
Catassi, C.; et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of
Coeliac Disease. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 136–160. [CrossRef] [PubMed]
22. Cole, T.J.; Bellizzi, M.C.; Flegal, K.M.; Dietz, W.H. Establishing a standard definition for child overweight and obesity worldwide:
International survey. BMJ 2000, 320, 1240. [CrossRef] [PubMed]
23. Cabré, R.; Jové, M.; Naudí, A.; Ayala, V.; Piñol-Ripoll, G.; Gil-Villar, M.P.; Dominguez-Gonzalez, M.; Obis, È.; Berdun, R.;
Mota-Martorell, N.; et al. Specific Metabolomics Adaptations Define a Differential Regional Vulnerability in the Adult Human
Cerebral Cortex. Front. Mol. Neurosci. 2016, 9, 138. [CrossRef] [PubMed]
24. Dunn, W.B.; Broadhurst, D.; Begley, P.; Zelena, E.; Francis-McIntyre, S.; Anderson, N.; Brown, M.; Knowles, J.D.; Halsall, A.;
Haselden, J.N.; et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid
chromatography coupled to mass spectrometry. Nat. Protoc. 2011, 6, 1060–1083. [CrossRef]
25. Broadhurst, D.; Goodacre, R.; Reinke, S.N.; Kuligowski, J.; Wilson, I.D.; Lewis, M.R.; Dunn, W.B. Guidelines and considerations for
the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic
studies. Metabolomics 2018, 14, 72. [CrossRef]
26. Chong, J.; Wishart, D.S.; Xia, J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Curr.
Protoc. Bioinform. 2019, 68, e86. [CrossRef]
27. Chong, J.; Xia, J. MetaboAnalystR: An R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 2018,
34, 4313–4314. [CrossRef]
28. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria,
2018; Available online: http://www.R-project.org/ (accessed on 6 July 2019).
29. Kolde, R. pheatmap: Pretty Heatmaps. 2019. Available online: https://CRAN.R-project.org/package=pheatmap (accessed on
15 September 2020).
30. Gordon, M.; Lumley, T. Forestplot: Advanced Forest Plot Using ’Grid’ Graphics. R Package Version 1.10. 2020. Available online:
https://CRAN.R-project.org/package=forestplot (accessed on 12 April 2021).
31. Wishart, D.S.; Feunang, Y.D.; Marcu, A.; Guo, A.C.; Liang, K.; Vázquez-Fresno, R.; Sajed, T.; Johnson, D.; Allison, P.; Karu, N.;
et al. HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res. 2018, 46, D608–D617. [CrossRef]
32. Tenori, L.; Oakman, C.; Morris, P.G.; Gralka, E.; Turner, N.; Cappadona, S.; Fornier, M.; Hudis, C.; Norton, L.; Luchinat, C.; et al.
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at
increased risk of disease recurrence. Results from a retrospective study. Mol. Oncol. 2015, 9, 128–139. [CrossRef]
Nutrients 2021, 13, 2271 10 of 10
33. Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.; Beger, R.; Daykin, C.A.; Fan, T.W.M.; Fiehn, O.; Goodacre, R.; Griffin, J.L.; et al.
Proposed minimum reporting standards for chemical analysis. Chemical Analysis Working Group (CAWG). Metabolomics
Standards Initiative (MSI). Metabolomics 2007, 3, 211–221. [CrossRef]
34. Freeman, H.J. Endocrine manifestations in celiac disease. World J. Gastroenterol. 2016, 22, 8472–8479. [CrossRef] [PubMed]
35. Carrasco, S.; Merida, I. Diacylglycerol, when simplicity becomes complex. Trends Biochem. Sci. 2007, 32, 27–36. [CrossRef]
[PubMed]
36. Almena, M.; Merida, I. Shaping up the membrane: Diacylglycerol coordinates spatial orientation of signaling. Trends Biochem. Sci.
2011, 36, 593–603. [CrossRef]
37. Sakane, F.; Hoshino, F.; Murakami, C. New Era of Diacylglycerol Kinase, Phosphatidic Acid and Phosphatidic Acid-Binding
Protein. Int. J. Mol. Sci. 2020, 21, 6794. [CrossRef] [PubMed]
38. Sedda, S.; DiNallo, V.; Marafini, I.; Franzè, E.; Paoluzi, O.A.; Izzo, R.; Giuffrida, P.; Di Sabatino, A.; Corazza, G.R.; Monteleone, G.
mTOR sustains inflammatory response in celiac disease. Sci. Rep. 2020, 10, 10798. [CrossRef]
39. Johnson, C.; Gonzalez, F.J. Challenges and opportunities of metabolomics. J. Cell. Physiol. 2011, 227, 2975–2981. [CrossRef]
[PubMed]
